Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Prostate cancer radiotherapy planning with Gallium-labelled PSMA-11 PET/CT imaging

Jeremie Calais • 6 Mar 2019
GU Cancers 2019
Genitourinary Cancer Prostate Cancer

Jeremie Calais, MD, of the University of California, Los Angeles, CA, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA and discusses a Phase III randomised trial study (NCT03582774) investigating the efficacy of radiotherapy planning using Gallium-labelled PSMA-11 PET/CT imaging.

More from Jeremie Calais

2:10
Exploring the new frontier: radionuclide therapy in metastatic prostate cancer
Jeremie Calais • 3 Jun 2023
4:16
PSMA PET guided salvage RT among patients with prostate cancer in the post-prostatectomy setting
Jeremie Calais • 3 Jun 2023
2:10
Integrating radioligand therapy for prostate cancer in US clinical practice
Jeremie Calais • 4 Jun 2023
2:56
PSMA PET ratio predicts response to [177Lu]PSMA radioligand therapy: a multicenter study
Jeremie Calais • 4 Jun 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals